Late-occurring Venous Thromboembolism in Allogeneic Blood or Marrow Transplant Survivors - a BMTSS-HiGHS2 Risk Model. Blood Adv. 2021.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4(12):2810-2820.
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123-3131.
Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2019.
Monocyte subpopulation recovery as predictors of hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant. 2019.
The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe). Biol Blood Marrow Transplant. 2018.
Proteome Profiling in Lung Injury Following Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016.
Infections following Transplantation of Bone Marrow or Peripheral-Blood Stem Cells from Unrelated Donors. Biol Blood Marrow Transplant. 2015.
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells from MDS patients against primary MDS and MDSC CD33+ targets. Blood. 2014.
CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.